Inclusion Criteria:

- Men

- Age of 40 years or greater

- Diagnosis of advanced prostate cancer (ie: prostate-specific antigen [PSA] less than
25 ug/L and undergoing continued treatment with leuteinizing hormone-releasing
hormone [LHRH] therapy)

- Willing and able to consent

Exclusion Criteria:

- Metastatic disease to bone

- Medications affecting bone turnover (bisphosphonate, steroids, anticonvulsant)

- Renal failure (serum creatinine > 200 umol/L)

- Co-morbidity factors affecting bone density (ie: Paget's, rheumatoid arthritis)

- Factors affecting ability to perform the bone density tests using femoral head
measurements (ie: bilateral hip arthroplasty)

- Cancer other than skin, except when, in the investigators' opinion, it is determined
to be appropriate and not adversely affect the outcome of the trial

- Gastrointestinal (GI) pathology (eg. malabsorption syndrome)

- Parathyroid disease